Journals / Viral Hepatitis Journal / 2014 / Cilt: 20 - Sayı: 1

Nüks Kronik Hepatit C Tedavisi Sırasında Gelişen Likenoid İlaç Reaksiyonu

Lichenoid Drug Reaction Developing During the Treatment of Recurrent Chronic Hepatitis C

Pages
32–35
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that an awareness of this possibility among physicians would help preventing any unnecessary dose reductions or discontinuations during PEG-IFN-α2b/ribavirin combination therapies, and thus contribute to a higher rate of permanent viral response among patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Lichenoid drug reaction is a cutaneous reaction that resembles lichen planus.
📊
Key Findings & Data:In this case, we present a female patient who received pegylated-interferon-alpha 2b (PEG-IFN-α2b)/ribavirin therapy for recurrent chronic hepatitis C virus (HCV) infections, and who developed a lichenoid drug reaction during the fifth month of her treatment.
💡
Conclusion & Impact:We believe that an awareness of this possibility among physicians would help preventing any unnecessary dose reductions or discontinuations during PEG-IFN-α2b/ribavirin combination therapies, and thus contribute to a higher rate of permanent viral response among patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Lichenoid drug reaction is a cutaneous reaction that resembles lichen planus. Lichenoid eruptions are classified as type IV delayed hypersensitivity reactions. Although rarely, interferons may also play a role in their etiology. In this case, we present a female patient who received pegylated-interferon-alpha 2b (PEG-IFN-α2b)/ribavirin therapy for recurrent chronic hepatitis C virus (HCV) infections, and who developed a lichenoid drug reaction during the fifth month of her treatment. Administration of a topical steroid and antihistamine treatment for a period of one month allowed the patients’ symptoms to be treated, and a permanent viral response to be achieved, without discontinuing the PEG-IFN-α2b/ribavirin therapy, xerosis and eczematous skin lesions that occur during the treatment of chronic HCV infection can be managed with moisturizers and topical steroids. We believe that an awareness of this possibility among physicians would help preventing any unnecessary dose reductions or discontinuations during PEG-IFN-α2b/ribavirin combination therapies, and thus contribute to a higher rate of permanent viral response among patients.

Özet

Likenoid ilaç reaksiyonu, liken planusa benzeyen kutanöz ilaç reaksiyonudur. Likenoid erüpsiyonlar Tip IV gecikmiş hipersensitivite reaksiyonlarıdır. Etiyolojisinde interferonlar nadir de olsa rol oynamaktadır. Bu çalışmada, nüks kronik hepatit C virüs (HCV) enfeksiyonu tanısı ile pegile-interferon- alfa2b (PEG-IFN-α2b)/ribavirin tedavisi alan ve tedavisinin beşinci ayında likenoid ilaç reaksiyonu gelişen bir kadın hasta sunulmuştur. PEG-IFN-α2b/ ribavirin tedavisini kesmeye gerek kalmadan, bir ay süre ile topikal steroid ve antihistaminik tedavi ile şikâyetleri iyileşen hastada kalıcı viral yanıt elde edilmiştir. Kronik HCV enfeksiyonu tedavisi esnasında ortaya çıkan kserozis ve ekzematöz lezyonlar nemlendirici ve topikal steroidler ile kontrol altına alınabilir. Bu durumun hekim tarafından bilinmesinin, gereksiz doz azaltılması veya kesilmesini önleyerek, hastaların kalıcı viral yanıtını artıracağını düşünmekteyiz.

🔖

Cite This Article

KADER, Ç., ÇÖLGEÇEN, E. Ö., SEÇKİN, S., ERBAY, A. (2014). Nüks Kronik Hepatit C Tedavisi Sırasında Gelişen Likenoid İlaç Reaksiyonu. Viral Hepatitis Journal, Cilt: 20 - Sayı: 1, 32–35. https://ajindex.com/articles/332714

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Adışen e, Gürer MA. Dermatolojik İstenmeyen etkiler ve Yaklaşım. Arman D, Leblebicioğlu H (ed). Kronik hepatit c tedavisi ve tedaviye bağlı istenmeyen etkilerin yönetimi. 1.Baskı, Ankara, Bilimsel Tıp, 2009: 71-78
  2. Barut HŞ, Günal ö, Yüksek J, sezer e. Kronik hepatit c tedavisinin mukozal-dermal yan etkileri. Viral Hepatit Dergisi. 2009; 14: 7-12
  3. Jadali z. Dermatologic Manifestations of Hepatitis c Infection and the effect of Interferon Therapy: A Literature review. Arch Iran Med. 2012; 15: 43-48
  4. Akman Aşık s, Köse Ş, Halıcıoğlu O, Bayol s, Alper s. Kronik hepatit B enfeksiyonunda pegile Interferon tedavisi sonrasında gelişen psörisasis: olgu sunumu. Viral Hepatit Dergisi. 2009; 14:77-80
  5. Ketikoglou I, Karatapanis s, elefsiniotis I, Kafiri G, Moulakakis A. extensive psoriasis induced by pegilated interferon alpha-2b treatment for chronic hepatitis B. eur J Dermatol. 2005; 15: 107- 109
  6. Gota c, calabrese L. Induction of clinical autoimmune dissease by therapeutic interferon-alpha. Autoimmunity. 2003; 36: 511- 518
  7. Deureure O, raison-Peyron n, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesion in patients treated with interferon alpha and ribavirin for hepatitis c; a series of 20 patients. Br J Dermatol. 2002; 147: 1142-1146
  8. Hashimoto Y, kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis c virus. J Dermatol. 2007; 34: 577-582
  9. Maddrey Wc. safety of combination interferon alpha-2b/ ribavirin theraphy in chronic hepatitis c-relapsed and treatment naive patients. semin Liver Dis. 1999; 19(suppl 1): 67-75
  10. Aspinall rJ, Pockros P J. The management of sideeffects during therapy for hepatitis c. Aliment Pharmacal Ther. 2004; 20: 917- 929
  11. Liibbe J, Kerl K, negro F, saurat JH. clinical and immunological features of hepatitis c treatment associated dermatitis in 36 prospective cases. Br J Dermatol. 2005; 153: 1088-1090
  12. Protzer u, Ochsendorf Fr, Leopolder-Ochsendorf A, Holtermuller KH. exa cerbation of lichen planus during interferon alpha-2a theraphy for chronic active hepatitis c. Gastroenterology. 1993; 104: 903-905. 13. erkek e. Kutanöz ilaç reaksiyonları, ilaçla ilişkili liken planus. ed.Tüzün Y, Gürer MA, serdaroğlu s, Oğuz O, Aksungur VL. Dermatoloji.cilt 1.3. Baskı, İstanbul, nobel Tıp Kitabevleri, 2008; s:285-286.